Histatin5 (Hst-5) is a member of the histatin family of antimicrobial peptides secreted by human parotid and submandibular glands. With the natural antibacterial activity, it plays an important role in the first-line barrier of oral cave against pathogens, especially for the fungal intrusion. In this study, we explored the utility of Hst-5 in the treatment of vulvovaginal candidiasis, a common condition of women of the childbearing age. We used a synthesized Hst-5 over five consecutive days as the topical treatment in a murine model of vulvovaginal candidiasis. According to the fungal colony counts, fungal burden in the vagina lavage dropped remarkably after treatment with Hst-5. Furthermore, cytological analysis of the lavage fluid indicated that the number of cast-off cells including cornified epithelial cells and inflammatory cells also decreased; histological evaluation of the vagina tissue revealed less fungi adhering to the vaginal wall in treated animals than in controls. Combined, these results suggested for the first time the potential utility of Hst-5 as a topical treatment for vulvovaginal candidiasis, uncovering the possibility of exploiting the natural antibiotic peptides in other aspects.
INTRODUCTION
Vulvovaginal candidiasis (VVC) is the second most common vaginal infection (Sobel 1988) . Approximately 75% of women have experienced one episode of VVC during their reproductive age, with 40%-50% having two or more episodes (Mitchell 2004) . Among all the Candida species isolated from patients with VVC, Candida albicans accounts for 76%-89% of all infection cases, followed by C. glabrata (7 to 16%), while C. krusei and C. tropicalis take up for 1%-4% and 1%-2%, respectively (Corsello et al. 2003; Holland et al. 2003; Vermitsky et al. 2008) . Candida albicans usually exists in the lower genitourinary tract as a member of normal microbial flora, but it could turns to be an opportunistic pathogen when the host is immunocompromised (Spampinato and Leonardi 2013) . Because of the changing demographics and the increasing reliance on immunosuppressive therapy, the incidence of fungal infections, including VVC, is rising (Arendrup et al. 2013) . Azoles constitute the front-line treatment for VVC, targeting and disrupting the cell wall by interfering the biosynthesis of ergosterol (Hof 2006) . The oral agent fluconazole and topical agent clotrimazole have been used as the routine clinical treatment against fungal infection (Spampinato and Leonardi 2013) . However, frequent exposure to these agents led to the emergence of azole-resistant C. albicans; the ratio of fluconazoleresistant candida species to all the isolates from patients with chronic use of antifungal agents is estimated to be 12.2% (Mulu et al. 2013) . Hence, the quest for new agents against for C. albicans, such as new imidazoles, fluconazole analogs, adducts of azoles and antimicrobial peptides, is the subject of intense investigation (Castelli et al. 2014) .
Histatins consisted a group of electrophoretically distinct histidine-rich proteins (Sabatini and Azen 1989; Troxler et al. 1990 ) that are exclusively secreted by the parotid and submandibular glands, and play an important part in the innate host defense against microbial infections in oral cavity (Oppenheim et al. 1988; Peters et al. 2010) . Histatin-5 (Hst-5), a 25-amino acid polypeptide that is a product of proteolytic cleavage from Histatin-3, has pronounced activity against C. albicans; it is most active at killing blastoconidia and germinated cells (Xu et al. 1991) . Its fungicidal activity is a consequence of a multistep process, with binding to the cell wall followed by the translocation to specific intracellular organelles (Li et al. 2006; Puri and Edgerton 2014) . Hst-5 disturbs mitochondrial functions and elicits oxidative stress; its lethality in C. albicans is associated with cell volume dysregulation that results from ion imbalance triggered by osmotic stress and release of small nucleotides, including ATP (Koshlukova et al. 1999; Vylkova, Sun and Edgerton 2007; Jang et al. 2010) . Some studies have revealed a significant fungicidal effect of Hst-5 both in vitro and in vivo without any drug resistance, suggesting a potential utility of Hst-5 as an anti-C. albicans agent (Situ and Bobek 2000; van't Hof et al. 2000; Peters et al. 2010) .
Given what is currently known about the antifungal activity of Hst-5, we aimed to determine its performance in treating VVC in vivo. We evaluated the effect of synthesized Hst-5 in a murine model of VVC. The results of the current study may inform the future clinical practice.
MATERIALS AND METHODS

Preparation of Hst-5 and other reagents
Hst-5 (DSHAKRHHGYKRKFHEKHHSHRGY, pI = 10.28, MW = 3036.33) was synthesized by Convenience Biology Co. (Changzhou, China). The peptide was purified by HPLC on a reversed phase C18-column. The purity of the synthetic peptide was 0.95%, as determined by peak integration with high-performed liquid chromatograms at 214 nm. The stocks of Hst-5 and bovine serum protein (BSA, Biosharp, Hefei, China), both 5 mM, were prepared in sterilized ultrapure water. Carboxymethyl cellulose sodium salt (CMC) purchased from Biosharp and suspended in sterilized ultrapure water at a concentration of 1%; the suspension supplemented with 0.01% Tween 80 was used as a vehicle. Clotrimazole was purchased from Tokyo Chemical Industry Co. (Tokyo, Japan) and was stored in ethanol at the concentration of 1 mg/1 μL; it was diluted in the vehicle solution to a final concentration at 0.5 mg/10 μL before use.
Cell preparation and culture
Candida albicans ATCC10231 purchased from American Type Culture Collection (ATCC, Manassas, USA) was used in the current study. The cells were grown in Sabouraud's dextrose agar (SDA), aerobically at 37
• C, and inoculated into Sabouraud's broth with shaking. Yeast cells in the exponential growth phase (OD 600 = 0.6) were used in all experiments. The viable blastoconidia were enumerated using a hemocytometer after trypan blue staining. Before the experiments, the cells were centrifuged at 3500 g (Minispin Spin, Eppendorf, Hamburg, Germany), washed twice with sodium phosphate buffer (NaPB, pH = 7.4) and suspended in NaPB to 10 6 colony-forming units (CFU)/mL or in phosphate-buffered saline to 10 8 CFU/mL.
Mouse model of VVC
Balb/c (H-2d) healthy female mice (6 to 8 weeks old, 16-18g) were used in the current study (n = 80). Six mice were housed in per cage, and supplied with food and water ad libitum. All mice were acclimated for 1 week in cages before the experiment. Care, maintenance and handling of the animals followed the requirements of NIH guidelines for animal experiments, and studies were performed in duplicate. The murine model of Candida vaginitis is described elsewhere (Yano and Fidel 2011) . Briefly, on day 1, each mouse received a subcutaneous injection of 100 μL of sesame oil (Bellancom Chemistry Co., Beijing, China) with 100 μg of estradiol valerate (E 2 ; Aladdin Industrial Co., Shanghai, China); this was repeated every 7 days during the experiment. On day 4, after inhalation anesthesia with isoflurane (Adamas Reagent, Ltd. Shanghai, China) in a respiratory chamber with the flow rate of oxygen at 2 L/min. each mouse was intravaginally inoculated with 20 μL of ATCC10231 (10 8 CFU/mL) via pipette tips. On day 6, the vagina of each animal was rinsed with 40 μL of phosphate-buffered saline (five times, with agitation); the rinse solutions were collected in a tube containing 160 μL of phosphate-buffered saline, for a total of 200 μL of the lavage fluid. The lavage fluid was diluted 40× in PBS (5-200 μL) and then plated on SDA containing 1.25 μg/mL chloramphenicol for fungal quantification. On days 8 to 12, mice with similar infection burdens were divided into six groups (10 mice in each group) to receive different treatments. The overview of the experiment is presented in Fig. 1 .
In vitro antifungal activity assays
To evaluate the yeast-form killing of Hst-5, fungicidal activity assays were performed using exponential-phase C. albicans cells and increasing concentrations of the peptide (2.5-50 μM). Candida albicans cells were washed twice with NaPB and then diluted in fresh NaPB to 10 6 CFU/mL; 50 μL of the suspension was added to the wells of a 96-well plate. Next, 50 μL of NaPB with different peptide concentrations were added the wells. An equivalent number of cells were incubated with 25 μM BSA or 1 μg/mL clotrimazole (Stevens et al. 2002) as controls. After gently mixing with pipette tip, the plate was incubated for 90 min at 37
• C with shaking at 80 rpm, and then the C. albicans suspensions were diluted in NaPB; 500 cells from each well were plated on SDA and incubated at 37
• C for 48 h, following which the CFUs were counted. The experiment was repeated on two independent occasions. To evaluate the hyphal-form inhibition, C. albicans cells were grown in RPMI 1640 medium supplemented with 2.5% heatinactivated fetal calf serum, 20 mM HEPES, 2 mM l-glutamine and 16 mM sodium hydrogen carbonate (pH 7.0), as described elsewhere (Wakabayashi et al. 1998) . Sterilized round slides for supporting the hyphae were placed at the bottom of each well of a 24-well plate before the addition of 100 μL of C. albicans culture (10 6 CFU/mL) and 400 μL of NaPB containing increasing peptide concentrations (5.0-50.0 μM), or 1 μg/mL clotrimazole, per well. After incubation for 14 h at 37
• C with shaking at 80 rpm, the solution was discarded without scraping the slides. Next, 100 μL of 70% ethanol was added to each well, the plate was gently shaken and the solution was discarded. Then, 100 μL of 0.02% crystal violet solution was added to the wells to stain the hyphae; after a 15-min incubation at 25
• C, the solution was discarded. Finally, the slides were rinsed twice with water and examined under a light microscope.
In vivo antifungal activity assays
Mice with similar infection burden (4-5 × 10 4 CFU/mL) were randomly divided into six groups, with mice per group. On days 8 to 12, three groups of mice received vaginal perfusion of 20 μL of the vehicle (CMC) with different concentrations of Hst-5 (either 10, 20 or 40 μM per one group) administered with pipette tips every single day. An identical amount of vehicle solution containing 20 μM BSA, 20 mg/mL clotrimazole (Stevens et al. 2002) or just the vehicle was given to the remaining three groups as control. The concentration range of Hst-5 was determined in the yeast form in vitro killing assays. The treatments were administered on five consecutive days. On day 13, the animals were sacrificed by breaking the vertebra; the vaginal lavage fluid was then acquired from each mouse to quantify the vaginal fungal burden. It was also used for cytological analysis; the murine vagina was extracted for histological analysis, as illustrated in Fig. 1 .
Papanicolaou staining of lavage smears
The vaginal lavages samples (100 μL) were transferred to clean glass slides and spread with another clean glass slide. The liquid was allowed to dry at room temperature and the cells were fixed with 95% ethanol/glacial acetic acid. They were then stained as described by Papanicolaou (1942) , by sequentially dipping in hematoxylin, 3% ammonia solution, Orange G and EA50 solution. The cell nucleus was stained bluish-violet; cornified epithelial cells were stained orange or pink; and non-cornified cells were stained green or blue. All slides were examined under a light microscope.
Histological analysis of the vaginal tissue
Following the lavage, the vagina was extracted longitudinally, washed twice with phosphate-buffered saline and fixed in 10% neutral-buffered formalin (48 h at 4 • C). The tissues were then embedded in paraffin, and sectioned transversely into 3 to 4 μm thick sections. Tissue sections from every mouse were mounted on a poly-l-lysine-coated slide and stained with hematoxylin, eosin and periodic-acid/Schiff's reagent (McManus 1948) . The images were acquired using Leica DM1000 microscope (Leica Microsystems, Wetzlar, Germany).
Statistical analysis
Statistical analysis was done via R (Version 3.3.3) by the author. The CFU in vitro antifungal activity data were analyzed by ANOVA. For the in vivo antifungal activity, log 10 (CFU/mL) from each lavage sample, before and after treatment, represented the vaginal infection burden. The change in fungal burden upon the treatment was calculated as log 10 [(CFU/mL, before the treatment)-(CFU/mL, after the treatment)]. The data were analyzed using a paired sample t-test, with significance cut-off set at P < 0.05.
RESULTS
In vitro antifungal activity assays reveal the efficacy of Hst-5 against Candida albicans
For yeast-form killing, average 429 ± 35 CFU/plate were evident on the control group SDA plates after incubation for 48 h at 37
The number of colonies decreased with an increasing Hst-5 concentration. The number of colonies significantly decreased from 407 ± 24 at 2.5 μM Hst-5 to 199 ± 18 at 20 μM Hst-5 (P < 0.05); the median lethal dose was determined to be between 15 μM and 20 μM Hst-5. For cells incubated with 20 μM BSA before plating on SDA, the colony number (448 ± 19) was not significantly different from the control. Likewise, the growth of cells was not • C with shaking at 80 rpm, followed by counting the CFU on SDA plates in each well. PBS, 20 μM BSA and 1ug/mL clotrimazole were taken as controls. Hst-5 showed a dose-dependent inhibition effect on the growth of C. albicans. The number of colonies on the SDA agar decreased from 407 ± 24 to 199 ± 18 (P < 0.05) when concentration of histatin-5 was increased from 2.5 to 20 μM. The 20 μM BSA, 1 μg/mL clotrimazole showed no inhibition on the growth of this strain compared to the blank control (B). P < 0.05 ( * ), P > 0.05 ( ).
affected by a treatment with 1 μg/mL of clotrimazole (411 ± 27 colonies), i.e. no significant difference from the control was apparent; this may be because the assay time was too short for the drug to exert its effect. In conclusion, the experiments revealed that Hst-5 exerts a strong dose-dependent fungicidal effect on C. albicans ATCC 10231 in vitro. Results were displayed in Fig. 2 .
For hyphal-form inhibition, microscopic observations of the control samples (not exposed to Hst-5 or clotrimazole) revealed large amounts of tangled, long and thin hyphae; the hyphae tips stained violet, and the intersepta were scarcely visible (Fig. 3) . In comparison, fewer hyphae and some yeast cells were present in samples treated with clotrimazole (Fig. 3A) ; the hyphae body Figure 3 . Hst-5 showed a dose-dependent inhibition effect on the hyphal form of C. albicans ATCC10231 in vitro. Candida albicans cells were grown on sterilized round slides in RPMI 1640 medium supplemented with 2.5% heat-inactivated fetal calf serum, 20 mM HEPES, 2 mM l-glutamine and 16 mM sodium hydrogen carbonate (pH = 7.0), added with increasing concentrations of Hst-5 (5.0-50.0 μM). After incubation for 14 h at 37
• C with shaking at 80 rpm, the hyphae in each slide was observed under a light microscope. PBS and 1 μg/mL clotrimazole were taken as controls. Large amounts of tangled, long and thin hyphae (black arrow) and none yeast form cells were seen in control samples without Hst-5 or clotrimazole. Fewer hyphae and some yeast cells (black triangle) were present in samples treated with 1 μg/mL clotrimazole. Hyphae formation was less apparent than in the control group, but more apparent than in the clotrimazole group when samples were exploded to 5μM Hst-5. Fewer hyphae with shorter and remarkably fewer branches in the presence of 25 μM Hst-5 than ones in the presence of 5 μM Hst-5. Only few hyphae and yeast cells were detected in the samples grown with 50 μM Hst-5. Scale bars, 100 μm (A), 20 μm (B).
and branches frequently formed bundles, and hyphae growth was impaired as suggested by the disappearance of hyphae tips, with clearly stained intersepta. In the presence of 5 μM Hst-5, hyphae formation was less apparent than in the control group, but more apparent than in the clotrimazole group (Fig. 3 ). When exposed to 25 μM Hst-5, fewer hyphae were formed, and they were shorter and with remarkably fewer branches than ones produced in the presence of 5 μM Hst-5 (Fig. 3) . At an even higher concentration of Hst-5 (50 μM), only few hyphae and yeast cells were detected, suggesting that the growth was largely inhibited; the remaining hyphae developed fewer branches than in other groups (Fig. 3) . These results suggested that 5 μM, 25 μM and 50 μM Hst-5 inhibited the growth of C. albicans ATCC 10231 as well as its ability to form hyphae. Moreover, higher Hst-5 concentration had a greater fungistatic effect than lower concentration.
The topical treatments of Hst-5 contribute to relieve the infection burden in vivo
The vaginal lavage was performed immediately after the animals had been sacrificed, 24 h after the final day of a 5-day treatment. Notably, the number of C. albicans cells recovered from the vaginal lavage fluid was significantly reduced in mice that had received 20 mg/mL clotrimazole, 20 μM Hst-5 or 40 μM Hst-5 in comparison with 10 μM Hst-5 and 20 μM BSA and the vehicle.
Because of the natural immune responses, the fungal murine burden was also somewhat reduced after treatment with a vehicle (3.61 ± 0.50 log 10 CFU/mL), BSA (3.05 ± 0.89 log 10 CFU/mL) or 10 μM Hst-5 (3.13 ± 0.43 log 10 CFU/mL) (P < 0.05), as compared with fungal burdens before treatment (on average, 4.15 ± 0.68 log 10 CFU/mL). In particular, following the treatment with 20 mg/mL clotrimazole, a significant reduction of fungal burden was observed, with 0.72 log 10 CFU/mL retrieved from the vaginal lavage (P < 0.01). Similarly, after completion of the 5-day treatment with 20 μM Hst-5 and 40 μM Hst-5, the vaginal fungal burdens in infected mice dropped to 0.63 log 10 CFU/mL and 0.58 log 10 CFU/mL, respectively (P < 0.01) (Fig. 4A ). Comparing the fungal burden before and after treatment, no differences between these groups that animals treated with the vehicle, BSA or 10 μM Hst-5 were apparent, and no differences between those groups that animals treated with 20 μM Hst-5, 40 μM Hst-5 or clotrimazole were observed. However, the changes in animal groups received vehicle, BSA or 10 μM Hst-5 were distinct from animal groups received 20 μM Hst-5, 40 μM Hst-5 or clotrimazole (P < 0.05) (Fig. 4B) , suggesting that additional factors were responsible for the decreased murine fungal burdens in the latter groups than just immunity. Nonetheless, the findings suggested that the topical use of Hst-5 (20 and 40 μM) constituted a feasible approach for treating murine VVC.
Papanicolaou staining of lavage smears
In samples from healthy mice, only a few anucleated cornified epithelial cells were observed; the epithelial cells were uniformly stained pink and were polygonal, with no inflammatory cells apparent, which was indicative of a successful artificial pseudoestrus (Fig. 5) . In contrast, in samples from mice inoculated with fungi prior to treatment, many cornified squamous epithelial cells were detected, with a concomitant influx of inflammatory cells (stained blue). Following a 5-day treatment, in samples from mice receiving a vaginal topical treatment with the vehicle (CMC) or BSA, markedly fewer epithelial cells than before the treatment were apparent, with copious numbers of inflammatory cells. When the animals were treated with 10 μM Hst-5, no obvious changes in the rough number of epithelial cells and inflammatory cells were observed. In contrast, at higher doses of Hst-5 (20 and 40 μM), clearly fewer epithelial cells and fewer inflammatory cells were apparent. Similar results were obtained when the infected mice were treated with 20 mg/mL clotrimazole. As noted under ×400 magnification, epithelial cells and inflammatory cells clustered around the hyphae (Fig. 5B ).
Histological analysis of the vaginal tissue
Compared with the healthy mice, with no C. albicans in the vaginal cavity, vaginal samples from infected animals contained vast numbers of filamentous pseudohyphae and blastoconidia adhering to the cornified epithelial layer (Fig. 6) . Furthermore, endocytosed hyphae and neutrophil infiltration were also evident in the mucosal layer. After treatment with the vehicle (CMC) or BSA, fewer pseudohyphae and blastoconidia were observed than before the treatment (Fig. 6 ). Vaginal administration of low amount of Hst-5 (10 μM) did not result in a visible change in numbers of pseudohyphae and blastoconidia compared to the controls, in agreement with the colony count data. When the concentration of Hst-5 was increased to 20 and 40 μM, noticeably fewer C. albicans cells were detected in the vaginal cavity and the cornified epithelium layer; the same degree of C. albicans ATCC 10231 growth inhibition was observed in vaginal samples of mice treated with 20 mg/mL clotrimazole (Fig. 6) .These results were in agreement with the lavage fluid colony counts, which indicated that 10 μM Hst-5 did not efficiently inhibit C. albicans ATCC10231 in vivo, while the effect of a higher concentration of Hst-5 (20 and 40 μM) was similar to the effect of clotrimazole.
DISCUSSION
It is well known that the development of any microbial infection depends on the pathogenic microorganism and the host, and the imbalance of these two leads to diseases. Specifically, women who take oral contraceptives, under long-term broad antibiotic treatment, or suffer from uncontrolled diabetes mellitus and immunodeficiency are prone to VVC (Cassone 2015) . Notably, Candida albicans, a commensal and opportunistic pathogen of human, is responsible for most cases of VVC. Characteristically, the pathogenic properties of C. albicans correlate with an environment or other factor-driven morphogenetic change; hence, commensalism is associated with the ovoid-shaped budding yeasts, and pathogenicity is linked to elongated ellipsoid cells, namely hyphae (Gow et al. 2012; Mayer, Wilson and Hube 2013) . Antimicrobial peptides found in the skin and mucosal barrier, as one of the innate immunity factors, serve as the first line of host defense against the intrusion of pathogenic microorganisms (Nizet et al. 2001; Chromek et al. 2006) . Specifically, in the female reproductive tract, antimicrobial peptides exhibit a wide range of functions to restrict microbial invasion or replication within host cells, and also modulate the immune system (Chromek et al. 2006; Wira, Rodriguez-Garcia and Patel 2015; Yarbrough, Winkle and Herbst-Kralovetz 2015) . Histatin-5, a member of histatin family in human saliva fluid, is a vital anti-Candida component of oral innate immune defenses; its antifungal activity is proportional to its concentration (Khurshid et al. 2017) . In HIV patients, reduced Hst-5 levels may be responsible for impaired the fungal killing and frequent oral candidiasis (Khan et al. 2013) . The value of histatin-5 as an efficient treatment for fungal infection had been already noticed as suggested in study by Kong et al. (2016) that Hst-5 released from a biocompatible hydrogel delivery system exhibited a rapid killing ability against C. albicans in murine oral candidiasis in vivo. The electrostatic and hydrogen bonding interactions between the peptide and the microorganism, rather than a particular molecular structure, initiate the antimicrobial activity (Raj, Marcus and Sukumaran 1998) . In the acid aqueous solution (pH < 3.8), histatin-5 is charged positively and remains unstructured and antifungal activity. Therefore, considering the pH of the female vagina (pH < 4.5), Hst-5 might be a good candidate for VVC 20 or 40 μM per one group) with pipette tips every single day. The fungal burden of murine VVC was calculated by log10 (CFU/mL) in the vaginal lavage. The change in fungal burden upon the treatment was calculated as log10 [(CFU/mL, before the treatment)-(CFU/mL, after the treatment)]. The changes of fungal burdens in all groups were significant after 5-day treatment from 4.15 ± 0.68 log10 CFU/mL before treatment to 3.61 ± 0.50 log10CFU/mL (vehicle CMC group), 3.05 ± 0.89 log10 CFU/mL (BSA group), 3.13 ± 0.43 log10 CFU/mL (10 μM Hst-5 group) (P < 0.05), but changes were more remarkable in groups treated with clotrimazole group (0.72 log10CFU/mL), 20 μM Hst-5 group (0.63 log10CFU/mL) and 40 μM Hst-5 group (0.58 log10 CFU/mL) (P < 0.01). P < 0.05 ( * ), P < 0.01 ( * * ), P > 0.05( ).
treatment since its function would not be compromise by the acidic vaginal environment. In the current study, in the in vitro antifungal experiment, RPMI 1640 medium mimicked the extracellular fluid, inducing the morphogenetic transformation of C. albicans. At 25 μM of Hst-5, much fewer mycelial phase cells with short hyphae (representing the fungal ability to invade the hosts) were apparent than in 5 μM of Hst-5 and blank control, suggesting the high concentration of Hst-5 did not only inhibit the proliferation of C. albicans ATCC 10231, but also inhibited its virulence. The hyphal inhibition data agreed with the yeast-form killing data.
Murine VVC is a useful model for studying fungal pathogenicity and host defenses. In the current study, each mouse was intravaginally inoculated with 20 μL of C. albicans (10 8 CFU/mL) 3 days after the injection of estradiol valerate; almost all mice developed VVC. Generally, colony counts from the vaginal lavage samples fluctuated around 4.15 ± 0.68 log 10 CFU/mL, with some deviation from average because of heterogeneity of immunity. Therefore, colony counts from lavage samples from each mouse before and after treatment were used as an indication of the severity of infection. As a topical treatment for infected mouse, 20 μL aliquots of different Hst-5 solutions were used; 20 μM was the optimal Hst-5 concentration since it was the minimal effective dose in vitro antifungal activity; we expanded the Hst-5 concentration range to half (10 μM) and double (40 μM) that dose to determine the effective dose in the murine model in vivo. As anticipated, no significant reduction of fungal burden was observed when 10 μM Hst-5 was used; however, 20 and 40 μM Hst-5 resulted in a remarkable inhibition of vaginal C. albicans (P < 0.05). Moreover, upon completion of treatment with 20 or 40 μM Hst-5, a remarkably smaller amount of white sediment was deposited at the bottom of vaginal lavage fluid tubes than in the control groups (data not shown); this sediment is similar to the typical cottage cheese-like vaginal discharge of women with VVC (Sobel 2007) , and our observations suggested less pronounced vaginal discharge in the infected mice after treatment. Furthermore, the cytological analysis of the vaginal lavage fluid revealed an effective reduction of inflammatory cells and cornified squamous epithelial cells after 20 and 40 μM Hst-5 treatments. This indicated that the tug of war between the host immune system and C. albicans lessened and the wall of the vagina was under less invasion than in the control groups.
In conclusion, our study of the fungicidal effect of Hst-5 on C. albicans ATCC 10231 revealed that a high concentration of Figure 6 . Histological analysis of vagina tissues with PAS staining. Vagina tissue was extracted longitudinally, fixed in 10% neutral-buffered formalin and then embedded in paraffin. Each section of paraffin-embedded tissues was stained with hematoxylin, eosin and periodic-acid/Schiff's reagent and then observed under Leica DM1000 microscope. The smooth cornified epithelial layer with no C. albicans cells were seen in tissues from healthy mice. Large amounts of filamentous pseudohyphae (black arrow) and blastoconidia adhering to the cornified epithelial layer and infiltration of neutrophil (red arrow) into the mucosal layer were observed in infected mice before treatment. Fewer pseudohyphae and blastoconidia were observed in tissues from mice receiving the vehicle (CMC), 20 μM BSA and 10 μM Hst-5 than before the treatment. Noticeably fewer C. albicans cells were detected in the vaginal cavity and the cornified epithelium layer in tissues from mice receiving 20 μM Hst-5, 40 μM Hst-5 or 20 mg/mL clotrimazole. Scale bars, 100 μm (A), 50 μm (B).
Hst-5 significantly inhibited the growth of this fungal strain in vitro and in vivo, uncovering the possibility of a topical usage of antimicrobial peptides against VVC.
